AUROPHARMA (5)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BSE announces the Offer to Buy (Buyback) acquisition window schedule for Aurobindo Pharma Ltd (AUROPHARMA), open from April 23 to April 29, … | |||||||||||||||
BSE announces the Offer to Buy (Buyback) acquisition window schedule for Aurobindo Pharma Ltd (AUROPHARMA), open from April 23 to April 29, 2026, at an offer price of Rs. 1475 per share for up to 54,23,728 equity shares.
| |||||||||||||||
BSE notifies opening of buyback offer by Aurobindo Pharma Limited to repurchase up to 54,23,728 equity shares at Rs.1,475 per share via … | |||||||||||||||
BSE notifies opening of buyback offer by Aurobindo Pharma Limited to repurchase up to 54,23,728 equity shares at Rs.1,475 per share via tender offer route, aggregating up to Rs.800 crore, open from April 23 to April 29, 2026.
| |||||||||||||||
BSE/ICCL announces the settlement calendar for Aurobindo Pharma Limited buyback acquisition window running from April 23 to April 29, 2026, … | |||||||||||||||
BSE/ICCL announces the settlement calendar for Aurobindo Pharma Limited buyback acquisition window running from April 23 to April 29, 2026, with settlement date of May 7, 2026.
| |||||||||||||||
BSE notifies trading members that Aurobindo Pharma Ltd has fixed April 17, 2026 as the record date for determining shareholder eligibility … | |||||||||||||||
BSE notifies trading members that Aurobindo Pharma Ltd has fixed April 17, 2026 as the record date for determining shareholder eligibility to participate in its equity share buyback offer.
| |||||||||||||||
NSE Clearing Limited imposes additional exposure margin of 15% in equity derivatives segment on 21 securities where top 10 clients account … | |||||||||||||||
NSE Clearing Limited imposes additional exposure margin of 15% in equity derivatives segment on 21 securities where top 10 clients account for more than 20% of MWPL, effective April 1, 2026.
| |||||||||||||||